- MAGIC Study
Trial Status
Closed
Cancer Type
Oesophageal Cancer
If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.
Protocol Title
A Randomised, Controlled Trial of Pre- and Post- Operative Chemotherapy in Patients with Operable Gastric and Lower Oesophageal Cancer.
Purpose of the Study
Surgery is the standard treatment for cancers of the stomach (gastric) and lower oesophagus (gullet) that can be removed with an operation, but the cancer often comes back (recurs) despite the best surgery. This trial will determine if adding chemotherapy two months before and two months after surgery improves recurrence and cure rates.
Principal Investigator
Prof Michael Findlay
Funding
Cancer Council NSW
DETAILED INFORMATION AVAILABLE
Available online at ClinicalTrials.Gov, please click here
Trial Status
Closed
Cancer Type
Oesophageal Cancer
If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.
Publication Reference
Cunningham D, Allum W, Stenning S, Thompson J, Van de Velde C, Nicolson M, Scarffe J, Lofts F, Falk S, Iveson T, Smith D, Langley R, Verma M, Weeden S, Chua Y, for the MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine 2007; 355(1): 11-20.
Conference Presentation Reference
Storey D; Australian Management Committee. MAGIC-MRC randomised trial of pre- and post-operative chemotherapy for operable gastric cancer: Insights from the Australasian Gastro-Intestinal Trials Group feasibility study (AG9601). 27th Annual Scientific Meeting of the Clinical Oncological Society of Australia; 28 Nov–1 Dec 2000; Adelaide.
Aim
Surgery is the standard treatment for cancers of the stomach (gastric) and lower oesophagus (gullet) that can be removed with an operation, but the cancer often comes back (recurs) despite the best surgery. This trial will determine if adding chemotherapy two months before and two months after surgery improves recurrence and cure rates.
Principal Investigator
Prof Michael Findlay, Medical Oncologist, Auckland Hospital, New Zealand
Funding
Cancer Council NSW
